Expectations trend
FY2028 · fiscal year ending 2028-09-30 · fmp
$-2.67 → $-2.67 · observed estimates
Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$10.08-5.35%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ENTA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Improve operating income | Management is focused on cutting losses and improving operating income. | Intact | operating income declines or stays flat beyond next 4 quarters | Operating income: $-17.236M FY2026-Q3; GAAP. Published target: operating income improves YoY. Target period is not explicitly aligned with this observation. Aug 12, 2026-17,236,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-09-30 · fmp
$-2.67 → $-2.67 · observed estimates
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 16, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, pipeline-driven biotechnology thesis rather than an established earnings compounder. The thesis is in a watch state: development work is progressing, but recent performance trails its industry cohort and confidence has eased to medium.
ENTA is described as cheap versus peers, but the valuation model has low confidence and its expectations gap is negative. The evidence labels pricing as justified, with low fragility, so the peer discount alone does not establish that the market is overlooking the business risks.
Near term, results may remain uneven: the company is loss-making, recent performance is neutral, and the elevated risk of an earnings miss reflects erratic surprises. Zelicapavir and oral immunology programs have reached development milestones, but supplied results show no product revenue from them; HCV royalty revenue fell year over year, and available cash resources declined between the first and second quarters while management still expects funding into fiscal 2029.
The multi-year thesis hinges on whether pipeline programs advance toward registrational development and eventually deliver financial contribution, while available resources support operations. Near-term guidance, continued weakening in jobs data, and earnings and guidance from healthcare bellwethers are stated swing factors; a CEO transition is also a recent event, though the evidence gives no details on its implications.
Over the next 1 to 3 years, ENTA remains a high-risk pipeline story with development progress but no demonstrated product revenue from its newer programs. The thesis depends on execution, funding runway, and whether near-term operating signals stabilize. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Enanta is working to improve cash flow, reducing negative cash from -$11.7M to -$7.16M. |
| Broken |
| cash flow remains negative beyond next 4 quarters |
Cash from operations: $-9.972M FY2026-Q3; GAAP. Published target: >= $0 positive cash flow. Target period is not explicitly aligned with this observation. Aug 12, 2026-9,972,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce net loss | A primary condition in Enanta Pharmaceuticals, Inc.'s published investment case. The stated target is net loss decreases YoY. | Broken | net loss grows or stays flat beyond next 4 quarters | Net income: $-19.501M FY2026-Q3; GAAP. Published target: net loss decreases YoY. Target period is not explicitly aligned with this observation. Aug 12, 2026-19,501,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Advance RSV drug trial plans | The company has a promising RSV drug trial that could drive future revenue. | Intact | trial delays or failures reported | Qualitative: RSV trial plans advancing June 2026 news reports Enanta stock rose on RSV drug trial plans, indicating progress without reported delays. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.06B → $0.06B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-10-01 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-02 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-03 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-04 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-05 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-06 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-07 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-08 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-09 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-10 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-11 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-12 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-13 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-14 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-15 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-16 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-17 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-18 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-19 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-20 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-21 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-22 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-23 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-24 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-25 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-26 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-27 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-28 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-29 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-30 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-10-31 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-11-01 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-11-02 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-11-03 | $-2.67 | $58,849,834 | 4 / 4 |
| 2026-11-04 | $-2.67 | $58,849,834 | 4 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.